Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial

Background Anacetrapib is the only cholesteryl ester transfer protein inhibitor proven to reduce coronary heart disease (CHD). However, its effects on reverse cholesterol transport have not been fully elucidated. Macrophage cholesterol efflux (CEC), the initial step of reverse cholesterol transport,...

Full description

Bibliographic Details
Main Authors: Mark P. Metzinger, Suzanne Saldanha, Jaskeerat Gulati, Kershaw V. Patel, Ayea El‐Ghazali, Sneha Deodhar, Parag H. Joshi, Colby Ayers, Anand Rohatgi
Format: Article
Language:English
Published: Wiley 2020-12-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
cholesteryl ester transfer protein
coronary heart disease
diabetes mellitus
haptoglobin genotype
sex
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.120.018136

Similar Items

Similar Items